Prevalence and clinical implications of conduction system disease in patients with cardiac transthyretin amyloidosis

Back

HFA Premium Access

Prevalence and clinical implications of conduction system disease in patients with cardiac transthyretin amyloidosis

Session: Treatment considerations in amyloidosis

Topic: Clinical

Speaker: Doctor L. Schlender (Frankfurt, DE)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Lara Sophie Schlender

University Hospital Frankfurt, Frankfurt (Germany)

1 presentation

0 follower

6 more presentations in this session

Systematic screening for transthyretic cardiac amyloidosis in patients undergoing TAVI: results from a greek-cypriot registry

Speaker: Doctor T. Tsampras (Athens, GR)

Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients

Speaker: Doctor J. Fernandes Pedro (Lisbon, PT)

Exploring tafamidis outcomes across varying disease severities in ATTR-CM

Speaker: Doctor C. Gregorio (Lisbon, PT)

Tafamidis and patient-reported outcomes in ATTR cardiomyopathy

Speaker: Mr D. Ferreira (Lisbon, PT)

Autonomic disfunction and peripheral neuropathy assessment by TILT and EMG in cardiac amyloidosis: insights from a high-volume single center.

Speaker: Doctor R. Carvalho (Lisbon, PT)

Access the full session

Treatment considerations in amyloidosis

Speakers: Doctor L. Schlender, Doctor T. Tsampras, Doctor J. Fernandes Pedro, Doctor C. Gregorio, Mr D. Ferreira...

Access

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources